Radioimmunodetection of amyloid deposits in patients with AL amyloidosis

Blood

Volumn 116, Issue 13, 2010, Pages 2241-2244

  Wall, Jonathan S ^a   Kennel, Stephen J ^a   Stuckey, Alan C ^a   Long, Misty J ^a   Townsend, David W ^a   Smith, Gary T ^a,b   Wells, Karen J ^a   Fu, Yitong ^a   Stabin, Michael G ^c   Weiss, Deborah T ^a,d   Solomon, Alan ^a  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN; IODINE 124; MONOCLONAL ANTIBODY;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; ISOTOPE LABELING; LIGHT CHAIN ASSOCIATED AMYLOIDOSIS; MALE; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; TISSUE DISTRIBUTION;

EID: 77957707133     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-273797     Document Type: Article

References (21)

1. Solomon A, Weiss DT. Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). Amyloid. 1995;2(4):269-279.
2. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45-59.
3. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596.
4. Gertz MA, Kyle RA. Amyloidosis: prognosis and treatment. Semin Arthritis Rheum. 1994;24(2):124-138.
5. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202-1207.
6. Palladini G, Anesi E, Perfetti V, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol. 2001;113(4):1044-1046. (Pubitemid 32634774)
7. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99(12):4276-4282. (Pubitemid 34627192)
8. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-yr study. Ann Intern Med. 2004;140(2):85-93.
9. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110(10):3561-3563.
10. O'Nuallain B, Allen A, Kennel SJ, Weiss DT, Solomon A, Wall JS. Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains. Biochemistry. 2007;46(5):1240-1247.
11. O'Nuallain B, Allen A, Atman D, Weiss DT, Solomon A, Wall JS. Phage display and peptide mapping of an immunoglobulin light chain fibril-related conformational epitope. Biochemistry. 2007;46(45):13049-13058. (Pubitemid 350086223)
12. Hrncic R, Wall JS, Wolfenbarger DA, et al. Antibody-mediated resolution of light chain-associated (AL) amyloid deposits. Am J Pathol. 2000;157(4):1239-1246.
13. Wall JS, Kennel SJ, Paulus M, et al. Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. J Nucl Med. 2006;47(12):2016-2024.
14. Davern S, Tang LX, Williams TK, et al. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol. 2008;130(5):702-711.
15. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-328.
16. Murphy CL, Wang S, Williams T, Weiss DT, Solomon A. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol. 2006;412:48-62. (Pubitemid 44548573)
17. Iznaga-Escobar N, Torres Arocha LA, Morales Morales A, Ramos Suzarte M, Rodríguez Mesa N, Pérez Rodríguez R. Technetium-99m- antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances. J Nucl Med. 1998;39(11):1918-1927.
18. Solomon A, Macy SD, Wooliver C, Weiss DT, Westermark P. Splenic plasma cells can serve as a source of amyloidogenic light chains. Blood. 2009;113(7):1501-1503.
19. 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med. 2006;119(4):355.e15-e24.
20. Solomon A, Weiss DT, Wall JS. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin Cancer Res. 2003;9(10 Pt 2):3831S-3838S.
21. Solomon A, Weiss DT, Wall JS. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm. 2003;18(6):853-860. (Pubitemid 38064016)